Proton Beam Therapy for Hepatocellular Carcinoma: Multicenter Prospective Registry Study in Japan

• DOI: 10.1016/j.ijrobp.2023.09.047
• Publication Date: 2023-09-30T07:40:19Z
• Authors: Masashi Mizumoto; Hiroyuki Ogino; Toshiyuki Okumura; Kazuki Terashima; Masao Murakami; Takashi Ogino; Hiroyasu Tamamura; Tetsuo Akimoto; Takahiro Waki; Norio Katoh; Masayuki Araya; Tsuyoshi Onoe; Masaru Takagi; Hiromitsu Iwata; Haruko Numajiri; Tomoaki Okimoto; Yusuke Uchinami; Kazushi Maruo; Kei Shibuya; Hideyuki Sakurai

IntroductionA prospective multicenter registry study was started in May 2016 Japan to evaluate the efficacy and safety of proton beam therapy (PBT) for hepatocellular carcinoma (HCC).MethodsPatients who received PBT HCC from June 2018 were registered database Particle Beam Therapy Committee Subcommittee Japanese Society Radiation Oncology (JASTRO). Overall survival (OS), progression-free (PFS) local recurrence evaluated.ResultsOf 755 cases, 576 with initial no duplicate cancer evaluated. At final follow-up, 322 patients alive 254 had died. The median follow-up period survivors 39 months (0-58 months). OS time 48.8 (95% CI 42.0-55.6 months) 1-, 2-, 3- 4-year rates 83.8% 80.5-86.6%), 68.5% (64.5-72.2%), 58.2% (53.9-62.2%), 50.1% (44.9-55.0%), respectively. Recurrence observed 332 including 45 cases. PFS 14.7 12.4-17.0 55.2% 51.0-59.2%), 37.5% (33.5-41.5%), 30.2% (26.3-34.2%), 22.8% (18.5-27.4%), significantly higher tumor size <5 vs. 5-10 cm (p<0.001) ≥10 (p<0.001); Child-Pugh score A/B C distance gastrointestinal tract <1 1-2 (p<0.008) >2 (p<0.001). 27 (4.7%) late adverse events grade 3 or higher, liver failure (n=7) dermatitis being most common.ConclusionThis data indicated that gives good therapeutic effects (3-year control rate 90%) a low risk severe events.